
David Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.

Your AI-Trained Oncology Knowledge Connection!


David Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.

David Ritchie, MD, PhD, discusses the rationale of the AIM trial in relapsed/refractory mantle cell lymphoma (MCL).

David Ritchie, MD, PhD, discusses the immunologic impact of long-term venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.

David Ritchie, MD, PhD, discusses the long-term immunological response to the combination of venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.

Published: February 6th 2020 | Updated:

Published: February 8th 2020 | Updated:

Published: February 18th 2020 | Updated:

Published: March 5th 2020 | Updated: